RESUMO
Divergent selection in mice for heat loss was conducted in 3 independent replicates creating a high maintenance, high heat loss (MH) and low maintenance, low heat loss (ML) line and unselected control (MC). Improvement in feed efficiency was observed in ML mice due to a reduced maintenance energy requirement but there was also a slight decline in reproductive performance, survivability, and lean content, particularly when compared to MC animals. The objective of this study was to model a life cycle scenario similar to a livestock production system and calculate total inputs and outputs to estimate overall biological efficiency of these lines and determine if reduced feed intake resulted in improved life cycle efficiency. Feed intake, reproductive performance, growth, and body composition were recorded on 21 mating pairs from each line × replicate combination, cohabitated at 7 wk of age and maintained for up to 1 yr unless culled. Proportion of animals at each parity was calculated from survival rates estimated from previous research when enforcing a maximum of 4, 8, or 12 allowed parities. This parity distribution was then combined with values from previous studies to calculate inputs and outputs of mating pairs and offspring produced in a single cycle at equilibrium. Offspring output was defined as kilograms of lean output of offspring at 49 d. Offspring input was defined as megacalories of energy intake for growing offspring from 21 to 49 d. Parent output was defined as kilograms of lean output of culled parents. Parent input was defined as megacalories of energy intake for mating pairs from weaning of one parity to weaning of the next. Offspring output was greatest in MC mice due to superior BW and numbers weaned, while output was lowest in ML mice due to smaller litter sizes and lean content. Parent output did not differ substantially between lines but was greatest in MH mice due to poorer survival rates resulting in more culled animals. Input was greatest in MH and lowest for ML mice for both offspring and parent pairs, consistent with previous results in these lines. Life cycle efficiency was similar in MC and ML mice, while MH mice were least efficient. Ultimately, superior output in MC mice slightly outweighed the lower inputs in ML animals resulting from decreased maintenance energy requirements. Therefore, selection to reduce maintenance energy requirements may be more useful in terminal crosses or in a selection index to reduce possible negative effects on output, especially reproductive performance.
Assuntos
Regulação da Temperatura Corporal/genética , Metabolismo Energético/fisiologia , Estágios do Ciclo de Vida/fisiologia , Modelos Biológicos , Seleção Genética/genética , Animais , Composição Corporal/genética , Composição Corporal/fisiologia , Digestão/fisiologia , Ingestão de Energia/genética , Ingestão de Energia/fisiologia , Metabolismo Energético/genética , Feminino , Estágios do Ciclo de Vida/genética , Tamanho da Ninhada de Vivíparos/genética , Camundongos , Paridade/fisiologia , Gravidez , Reprodução/genética , Reprodução/fisiologia , Taxa de SobrevidaRESUMO
Cold pressed and hexane extracted moringa seed oils (CPMSO and HEMSO) were evaluated for their physico-chemical and stability characteristics. The iodine value, saponification value and unsaponifiable matter of CPMSO and HEMSO were found to be 67.8 and 68.5 g I2 / 100 g oil, 190.4 and 191.2 mg KOH / g oil and 0.59 and 0.65%, respectively. The total tocopherols of CPMSO and HEMSO were found to be 95.5 and 90.2 mg/Kg. The fatty acid composition of CPMSO and HEMSO showed oleic acid as the major fatty acid (78-79%). The oxidative, thermal and frying stabilities of the CPMSO were compared with commercial raw and refined groundnut oil (GNO and RGNO). The CPMSO was of adequate thermal stability and better oxidative stability as it showed 79% lesser peroxide formation than GNO. The frying stability of CPMSO was better as it showed lower increase in free fatty acid (28%), peroxide value (10 meq O2/Kg) and color (25%) than RGNO (48%, 22 meq O2/kg and 52%, respectively) after frying.
RESUMO
Changes in maintenance energy requirements and in feed efficiency have been achieved by divergent selection for heat loss in mice in 3 replicates, creating high heat loss, high maintenance (MH) and low heat loss, low maintenance (ML) lines and an unselected control (MC). However, feed intake has mainly been measured in mature animals and not during growth or reproduction. Additionally, there is evidence that reducing maintenance energy will increase fat content, an undesirable result. To evaluate if selection has altered body composition and lifecycle feed intake, mating pairs were continuously mated and maintained for up to 1 yr unless culled. Offspring pairs were sampled from each line at each parity and maintained from 21 to 49 d of age. Feed intake was recorded for mating pairs throughout the year and on offspring pairs. Body weight was recorded on all animals at culling as well as percent fat, total fat, and total lean, measured by dual X-ray densitometry. Average daily gain was also recorded for offspring. Energy partitioning was achieved using 2 approaches: Approach I regressed energy intake of the pair on sum of daily metabolic weight and total gain to obtain maintenance (bm) and growth (bg) coefficients for each line, replicate, feeding period, and sex (offspring pairs only); Approach II calculated bm for each pair assuming constant energy values for lean and fat gain. Energy coefficients and body composition traits were evaluated for effect of selection (MH vs. ML) and asymmetry of selection ([MH + ML]/2 vs. MC). Both MC mating and offspring pairs tended to have greater BW than the average of the selection lines (P < 0.08). Males of offspring pairs weighed more than females (P < 0.01), while females of mating pairs weighed more than males (P < 0.01). Line was insignificant (P > 0.15) for body composition traits. Using Approach I, MH mice had a greater bm than ML mice for mating pairs (P = 0.03) but not offspring pairs (P = 0.50). For Approach II, MH had a greater bm than ML mice for both mating (P = 0.01) and offspring pairs (P = 0.01). The effect of selection for heat loss on body composition was smaller than previously reported and unlikely to outweigh the benefit of reduced feed intake, which was shown to be maintained throughout an entire lifecycle that included reproducing animals. Additionally, the reduction in energy intake seems primarily due to reduced maintenance energy costs, validating the success of the selection procedure.
Assuntos
Composição Corporal/genética , Regulação da Temperatura Corporal/genética , Ingestão de Alimentos/genética , Seleção Genética , Animais , Composição Corporal/fisiologia , Ingestão de Alimentos/fisiologia , Feminino , Masculino , CamundongosRESUMO
Divergent selection for heat loss was implemented in mice creating maintenance high (MH) and low maintenance (ML) lines and an unselected control (MC) in 3 independent replicates. Mice from the ML line have improved feed efficiency, due to decreased maintenance energy requirement, but there is potential for a correlated decline in reproductive performance and survivability. Number fully formed (NFF), number born alive (NBA), number weaned (NW), litter weaning weight (LWW), pup weaning weight (PWW), fraction alive at birth (FAB), fraction alive at weaning, and birth interval were recorded at every parity on 21 mating pairs from each line × replicate combination cohabitated at 7 wk of age and maintained for up to 1 yr. Traits were summed over parities to evaluate lifetime production. Pairs were culled due to death or illness, no first parity by 42 d cohabitation, 2 consecutive litters with none born alive, 3 consecutive litters with none weaned, 42 d between parities, or average size of most recent 2 litters less than half the average of first 3 litters. Survival probabilities were produced and evaluated for each line and used to calculate mean number of parities using a Markov-chain algorithm assuming a maximum of 4, 6, 8, 10, or 12 parities or 1 yr. Line was insignificant for all litter traits while NFF, NW, and FAB decreased with parity (P < 0.05) and PWW tended to increase (P < 0.07). The MC mice had higher lifetime NW, LWW, and PWW (P < 0.04). Birth interval showed that MH mice had increasingly larger intervals while remaining the same in ML mice (P < 0.01). In the survival analysis, MC mice had the greatest survival rates overall, but ML mice had the greatest rates in the period up to 5 parities while MH mice had the greatest rates in later parities. This resulted in greater mean number of parities for ML mice up to maximum of 8 parities and higher means for MH mice when the maximum number of allowed parities was 10 or higher. Reproductive performance was not substantially affected by changing maintenance energy requirements. The ML animals appear to survive well in early parities and produce more parities when a low number of maximum parities is enforced, but this benefit declines in later parities and MH animals survive better and increase mean number of parities when turnover rates are low. Therefore, selection for low maintenance animals may be beneficial for systems desiring a short generation interval but less so for systems desiring longevity.
Assuntos
Regulação da Temperatura Corporal/genética , Regulação da Temperatura Corporal/fisiologia , Tamanho da Ninhada de Vivíparos/fisiologia , Longevidade/fisiologia , Seleção Genética , Animais , Peso Corporal , Tamanho da Ninhada de Vivíparos/genética , Longevidade/genética , CamundongosRESUMO
REASONS FOR PERFORMING STUDY: Flunixin meglumine is used for treatment of equine colic despite evidence of inhibited recovery of mucosal barrier function following small intestinal ischaemic injury. This study aimed to characterise an alternative treatment (AHI-805) for abdominal pain in the horse. OBJECTIVE: To determine the effect of AHI-805, an aza-thia-benzoazulene derivative, on the cyclooxygenase enzymes and the recovery of mucosal barrier function following ischaemic injury. METHODS: Effect of AHI-805 on in vitro COX-1 and COX-2 activity was determined by measuring coagulation-induced thromboxane B(2) (TXB(2)) and lipopolysaccharide-stimulated prostaglandin E(2) concentrations in equine whole blood. Horses (n = 6) were anaesthetised and jejunum subjected to ischaemia for 2 h. Control and ischaemia injured mucosa was placed in Ussing chambers and treated with Ringer's solution containing control treatment (DMSO), flunixin meglumine (27 µmol/l), or AHI-805 (27 µmol/l). Transepithelial electrical resistance (TER), mucosal-to-serosal flux of (3) H-mannitol, and bathing solution TXB(2) and prostaglandin E metabolites (PGEM) were measured over a 4 h recovery period. RESULTS: Treatment with AHI-805 had no significant effect on TXB(2) production but significantly inhibited production of PGE(2) at a concentration of 1 µmol/l or greater. TER of flunixin or AHI-805 treated ischaemia-injured jejunum was significantly lower than control treated injured tissue over the recovery period. Mannitol flux and grade of histological damage were significantly increased by ischaemic injury only. There was a significant increase in PGEM and TXB(2) in control tissues over the 240 min recovery period, but not in flunixin or AHI-805 treated tissues. CONCLUSIONS: Flunixin meglumine and AHI-805 inhibit recovery of barrier function in ischaemic-injured equine jejunum in vitro through inhibition of the COX enzymes. POTENTIAL RELEVANCE: The novel compound AHI-805 may not be suitable for the treatment of equine colic associated with ischaemic injury.
Assuntos
Anti-Inflamatórios não Esteroides/farmacologia , Azulenos/farmacologia , Inibidores de Ciclo-Oxigenase/farmacologia , Cavalos/sangue , Isquemia/complicações , Jejuno/enzimologia , Jejuno/lesões , Animais , Cadáver , Clonixina/análogos & derivados , Ciclo-Oxigenase 1/sangue , Ciclo-Oxigenase 1/metabolismo , Ciclo-Oxigenase 2/sangue , Ciclo-Oxigenase 2/metabolismo , Impedância Elétrica , Mucosa Intestinal/efeitos dos fármacosRESUMO
Five years of adjuvant endocrine therapy with the antiestrogen tamoxifen has been shown to significantly reduce the risk of recurrence in women with early breast cancer and has thus been the standard of adjuvant therapy for this malignancy over the last two decades. Tamoxifen has also been used for the first-line treatment of advanced or metastatic breast cancer, and it was studied in the neoadjuvant setting to promote breast-conserving surgery in those patients who may be otherwise ineligible. However, comparative clinical trials involving the more recently approved third-generation aromatase inhibitor drugs (anastrozole, letrozole, and exemestane) have challenged tamoxifen as first-line therapy in advanced/metastatic breast cancer as well as in the neoadjuvant setting. Although trials with other AIs have shown improved efficacy and better tolerability over tamoxifen, letrozole has consistently demonstrated superiority over tamoxifen when used as first-line treatment for advanced/metastatic breast cancer or as neoadjuvant therapy. The efficacy of letrozole in the neoadjuvant setting further extends to those tumors with positive human epidermal growth factor receptor (HER1) and/or HER2 expression, which are often less responsive to tamoxifen. The encouraging results of such trials identify letrozole as a better alternative to tamoxifen in improving responses rates in the treatment of advanced breast cancer and as neoadjuvant therapy, which allows breast-conserving surgery in women with inoperable breast cancer or who were not candidates for breast-conserving surgery.
Assuntos
Inibidores da Aromatase/uso terapêutico , Neoplasias da Mama/tratamento farmacológico , Nitrilas/uso terapêutico , Triazóis/uso terapêutico , Inibidores da Aromatase/administração & dosagem , Neoplasias da Mama/patologia , Ensaios Clínicos como Assunto , Esquema de Medicação , Feminino , Humanos , Letrozol , Terapia Neoadjuvante , Metástase Neoplásica , Nitrilas/administração & dosagem , Terapia de Salvação , Triazóis/administração & dosagemRESUMO
Intratumoral aromatase is a therapeutic target for the treatment of post-menopausal estrogen-dependent breast cancers. Therefore, reliable methods should be developed for routine application for the detection of intratumoral aromatase. Immunohistochemistry (IHC) is considered one of the most suitable methods in this regard. A multi-centre collaborative group has been established to generate and validate new aromatase monoclonal antibodies. We have selected two monoclonal antibodies, #677 against native aromatase protein and F2 against formalin-fixed protein for this purpose. With these two monoclonal antibodies 43 cases of invasive ductal carcinoma, which had been previously assayed for aromatase activity by product isolation methodology, were immunostained in three laboratories in UK, USA and Japan and independently evaluated by three pathologists (H.S., T.A. and S.G.S.). Staining of malignant epithelium, adipose tissue, normal/benign and stromal compartments of the tumors were assessed by estimating the proportion of positive staining cells and the relative intensity of staining in this fashion. Immunoreactivity could be detected in each component of the tissue specimens but a significant positive correlation with biochemical activity was detected only in malignant epithelium stained with 677 not in other components with #677 and not in any of the components. Staining using F2 as a primary antibody did not produce a positive correlation in any components with aromatase activity. These results suggest that we now have a monoclonal antibody against aromatase (#677) which may be used to stain archival materials. A methodology and scoring system is recommended whereby staining significantly correlates with aromatase activity of the resected tissue specimens of breast cancer.
Assuntos
Anticorpos Monoclonais , Aromatase/análise , Neoplasias da Mama/enzimologia , Imuno-Histoquímica , Aromatase/imunologia , Neoplasias da Mama/diagnóstico , Feminino , HumanosRESUMO
Intratumoral aromatase is a potential therapeutic target for the treatment of postmenopausal estrogen-dependent breast cancers. Therefore, reliable methods should be developed for routine application for the detection of intratumoral aromatase. A multi-center collaborative group has been established to generate and validate new aromatase monoclonal antibodies (MAbs). A recombinant GST-aromatase fusion protein was expressed in baculovirus and the purified protein was used for immunization of mice either as a native or formalin-fixed antigen. Hybridomas were generated using standard techniques and screened biochemically prior to immunohistochemistry (IHC) evaluation in human placenta, ovary and breast cancer tissues. Twenty-three MAbs selected by biochemical assays were further evaluated by IHC of paraffin-embedded tissue sections including normal ovary, and placenta, and a small series of 10 breast carcinomas. Of the 23 MAbs, 2 (clones 677 and F2) were determined to specifically stain cell types known to express aromatase in normal tissues. In breast carcinomas staining of malignant epithelium, adipose tissue, normal/benign and stromal compartments was detected. IHC was performed and independently evaluated by three pathologists (HS, TJA and SGS), each using the same evaluation criteria for staining intensity and proportion of immunopositive cells. With these two MAbs, interpathologist and intralaboratory variations were minimal in comparison with differences which could be detected between tissue specimens and antibodies.
Assuntos
Anticorpos Monoclonais/imunologia , Aromatase/imunologia , Aromatase/metabolismo , Animais , Anticorpos Monoclonais/biossíntese , Anticorpos Antineoplásicos/imunologia , Anticorpos Antineoplásicos/metabolismo , Aromatase/análise , Aromatase/genética , Western Blotting , Neoplasias da Mama/enzimologia , Neoplasias da Mama/patologia , Linhagem Celular Tumoral , Feminino , Humanos , Imuno-Histoquímica/métodos , Camundongos , Ovário/enzimologia , Placenta/enzimologia , Proteínas Recombinantes de Fusão/imunologia , Proteínas Recombinantes de Fusão/metabolismoRESUMO
Recent clinical trials indicate that the third-generation aromatase inhibitors may be more effective than tamoxifen as first line endocrine therapy in ER+ metastatic breast cancer in postmenopausal women. This review will focus exclusively on the pharmacology of the non-steroidal inhibitor letrozole. Aromatase derived from a variety of sources is inhibited at low nM concentrations of the drug. In non-cellular systems, letrozole is 2-5 times more potent than anastrozole and exemestane in its inhibition of aromatase, whilst in cellular systems it is 10-20 times more potent. Anti-tumour effects of letrozole have been demonstrated in several animal models. In postmenopausal women, letrozole commonly suppresses circulating concentrations of estrone and estradiol to below the sensitivity limit of the assays used to measure them. In a recent randomized cross-over study, letrozole (2.5mg daily) achieved a significantly greater suppression of the plasma concentrations of both estrone and estrone sulphate than anastrozole (1mg daily) and a greater inhibition of in vivo aromatization. Letrozole appears to have a small effect on adrenal steroidogenesis such that a small number of patients exhibit an abnormal response to synthetic ACTH during letrozole therapy. This is unlikely to have any clinical significance. In short-term studies letrozole has been shown to increase markers of bone resorption indicating the need to monitor bone integrity when the drug is used for extended periods of time. A consistent effect of letrozole on serum lipids has not been demonstrated.
Assuntos
Antineoplásicos/farmacologia , Inibidores Enzimáticos/farmacologia , Nitrilas/farmacologia , Triazóis/farmacologia , Hormônio Adrenocorticotrópico/sangue , Animais , Antineoplásicos/efeitos adversos , Antineoplásicos/metabolismo , Aromatase/metabolismo , Inibidores da Aromatase , Neoplasias da Mama/tratamento farmacológico , Neoplasias da Mama/metabolismo , Neoplasias da Mama/secundário , Ensaios Clínicos como Assunto , Inibidores Enzimáticos/efeitos adversos , Inibidores Enzimáticos/química , Inibidores Enzimáticos/metabolismo , Estradiol/sangue , Estrona/análogos & derivados , Estrona/sangue , Humanos , Letrozol , Nitrilas/efeitos adversos , Nitrilas/química , Nitrilas/metabolismo , Triazóis/efeitos adversos , Triazóis/química , Triazóis/metabolismoRESUMO
An important feature of the pharmacological profile of aromatase inhibitors is the ability of the various inhibitors to inhibit intracellular aromatase. It is now well documented that a large proportion of breast tumors express their own aromatase. This intratumoral aromatase produces estrogen in situ and therefore may contribute significantly to the amount of estrogen to which the cell is exposed. Thus it is not only important that aromatase inhibitors potently inhibit the peripheral production of estrogen and eliminate the external supply of estrogen to the tumor cell, but that they in addition potently inhibit intratumoral aromatase and prevent the tumor cell from making its own estrogen within the cell. To study the inhibition of intracellular aromatase we have compared the aromatase-inhibiting potency of the non-steroidal aromatase inhibitors, letrozole, anastrozole and fadrozole in a variety of model cellular endocrine and tumor systems which contain aromatase. We have used hamsters ovarian tissue fragments, adipose tissue fibroblasts from normal human breast, the MCF-7Ca human breast cancer cell line transfected with the human aromatase gene and the JEG-3 human choriocarcinoma cell line. Although letrozole and anastrozole are approximately equipotent in a cell-free aromatase system (human placental microsomes), letrozole is consistently 10-30 times more potent than anastrozole in inhibiting intracellular aromatase in intact rodent cells, normal human adipose fibroblasts and human cancer cell lines. Whether these differences between letrozole and anastrozole are seen in the clinical setting will have to await the results of clinical trials which are currently in progress.
Assuntos
Inibidores da Aromatase , Aromatase/metabolismo , Inibidores Enzimáticos/farmacologia , Anastrozol , Animais , Cricetinae , Fadrozol/farmacologia , Humanos , Letrozol , Nitrilas/farmacologia , Triazóis/farmacologia , Células Tumorais CultivadasRESUMO
The role/need for estrogen in regulating testicular function of adult male bonnet monkeys (M. radiata) has been investigated by dosing orally a group of five normal males 2.5 mgs of CGP 47645, a long-acting nonsteroidal aromatase inhibitor (AI), once every 5 days for over 150 days. Such treatment resulted in a 10-fold increment in nocturnal serum testosterone (T) levels, which were sustained for 85 days of treatment, and a twofold increment in basal serum T levels was present throughout the 150 days of treatment. Analysis of ejaculated semen showed a marked reduction (approximately 90%) in sperm counts in four out of five monkeys between Days 55-85 of treatment. During this period, the motility score also was markedly reduced from a normal score of 3-5 to 0-2. Flow cytometric analysis of testicular germ cells obtained from biopsy tissue taken on Days 63 and 120 indicated a marked reduction only in elongating/elongated spermatid population (compared to Day 0 values), suggesting inhibition in spermiogenic process. Epididymal sperm maturation also seemed effected as sperm chromatin, on flow cytometric analysis for decondensability following exposure to 5 mM dithiotreitol, showed to be in a hypercondensed state. This study thus indicates that estrogen has an important role in providing normal testicular and sperm function in the primate.
Assuntos
Inibidores da Aromatase , Nitrilas/administração & dosagem , Testículo/enzimologia , Testículo/fisiologia , Triazóis/administração & dosagem , Administração Oral , Animais , Cromatina/efeitos dos fármacos , Cromatina/metabolismo , DDT/farmacologia , Inibidores Enzimáticos/administração & dosagem , Antagonistas de Estrogênios/administração & dosagem , Feminino , Injeções Intravenosas , Hormônio Luteinizante/administração & dosagem , Macaca radiata , Masculino , Sêmen/efeitos dos fármacos , Espermatogênese/efeitos dos fármacos , Testículo/efeitos dos fármacos , Testosterona/sangue , TempoRESUMO
The aim of endocrine therapy is to reduce the estrogenic stimulus for tumour growth. After failure of tamoxifen--the standard "first-line" hormonotherapy for advanced breast cancer (ABC)--the most frequently prescribed endocrine therapies are progestins and aromatase inhibitors (AIs) ("second-line" hormonotherapy). Estrogen deprivation through AIs provides effective treatment of hormone-dependent ABC in postmenopausal (PMP) women. Over the past few years, the goals of our research programme were to develop more potent, more selective and better tolerated AIs than our first AI, aminoglutethimide (AG). Lentaron (4-hydroxyandrostenedione, formestane), a highly selective steroidal compound was the first of the new AIs to be used in clinical trials. It is a substrate analogue, administered as an i.m. injection every 2 weeks. It is effective in the treatment of ABC with an objective response rate (ORR) similar to tamoxifen and megestrol acetate (MA) and is generally well tolerated; rare instances of injection site reactions have been reported. Afema (fadrozole HCl), a non-steroidal AI is active orally, and effectively suppresses estrogen levels in PMP women, but it is not completely selective for aromatase when administered at higher than therapeutic doses. At the therapeutic dose of 1 mg twice a day it has an anti-tumour efficacy similar to MA, a good tolerability and no clinically relevant effects on other hormones of the endocrine system. Letrozole is the fourth of our AIs in clinical development. It is a non-steroidal, achiral, orally active, potent and highly selective competitive AI. Clinical endocrine studies have shown that the dose of 0.5 mg a day is the lowest dose achieving maximum estrogen suppression. Over a wide dose range, a lack of clinically relevant effects on other hormones of the endocrine system has confirmed its high selectivity. In four phase Ib/IIa studies in PMP patients with ABC who failed previous therapy, letrozole produced ORRs of 9, 31, 33 and 36%. One phase IIb/III study has been completed and two others are ongoing, comparing two doses of letrozole with MA or AG to confirm the anti-tumour efficacy of letrozole in the treatment of ABC in PMP women after treatment with anti-estrogens. Preliminary results from the completed trial show that letrozole 2.5 mg is superior to 0.5 mg in terms of ORR, time to progression and time to treatment failure, and is superior to the standard dose of MA in terms of ORR and tolerability. Therefore letrozole 2.5 mg can be recommended as a first choice for the treatment of PMP patients with hormone receptor-positive or unknown ABC after anti-estrogen therapy.
Assuntos
Inibidores da Aromatase , Neoplasias da Mama/tratamento farmacológico , Inibidores Enzimáticos/uso terapêutico , Neoplasias da Mama/fisiopatologia , Antagonistas de Estrogênios/uso terapêutico , Feminino , Humanos , Resultado do TratamentoRESUMO
CGP 53153 (N-2-(cyano-2-propyl)-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carb oxamide) is a steroidal inhibitor of 5alpha-reductase, the enzyme which effects the conversion of testosterone (T) to 5alpha-dihydrotestosterone (DHT). In vitro, CGP 53153 competitively inhibited rat microsomal 5alpha-reductase from prostate by 50% (IC50) at a concentration of 36nM compared to the reference compound finasteride which inhibited 5alpha-reductase with an IC50 of 11 nM in the same system. In vivo, inhibition of 5alpha-reductase activity was characterized in three different test systems. Inhibition of 5alpha-reductase activity was first assessed in a standard test designed to compare directly the potency of different 5alpha-reductase inhibitors. This test assesses potency through the inhibition of prostate growth in juvenile castrate male rats treated with a standard dose of T-propionate (1 mg/kg, s.c.) and a 5alpha-reductase inhibitor administered orally at various doses for 4 days. CGP 53153 and finasteride significantly reduced T-propionate-mediated prostate growth by about 25% (ED25) compared to T-propionate-treated controls at oral doses of 0.01 and 0.1 mg/kg, respectively. Second, the effects on prostate weight were studied in normal adult male rats treated orally once daily for 14 days with 1, 3 and 10 mg/kg CGP 53153 and with 10 mg/kg finasteride. CGP 53153 significantly reduced prostate weight at 3 and 10 mg/kg by 31% and 37%, respectively, compared to vehicle-treated controls, whereas the dose of 10 mg/kg finasteride did not significantly reduce prostate weight. Third, the effects on prostate volume were studied in normal 6-9-year-old male dogs treated orally once daily with 5 mg/kg CGP 53153 and with 5 mg/kg finasteride for 12 weeks. Prostate volume was monitored with magnetic resonance imaging every 2 weeks beginning 6 weeks before start of the treatment with 5alpha-reductase inhibitors and ending after a recovery period of 8 weeks after termination of treatment. Treatment for 12 weeks with both CGP 53153 and finasteride was equally effective in reducing prostate volume by more than 70% in individual dogs. Anti-androgenic potency of CGP 53153 and finasteride was assessed in juvenile castrate male rats treated with DHT-propionate (1 mg/kg, s.c.) and a 5alpha-reductase inhibitor (p.o.) for 4 days. Neither CGP 53153 nor finasteride given at a dose of 10 mg/kg had any significant effect on DHT-propionate-mediated prostate growth, whereas the reference anti-androgen flutamide given at a dose of 10 mg/kg reduced prostate weight to levels comparable to those seen in untreated castrate animals. For CGP 53153, the dose of 10 mg/kg is 1000-fold higher than the ED25 for 5alpha-reductase inhibition in vivo. In conclusion, both CGP 53153 and finasteride are potent inhibitors of the rat 5alpha-reductase enzyme system in vitro without showing any anti-androgenic effects in vivo. Both CGP 53153 and finasteride were equally potent in reducing prostate volume in aged male dogs, whereas in rats, CGP 53153 is up to 10 times more potent than finasteride in reducing prostate weight as shown in two different rat models.
Assuntos
Inibidores de 5-alfa Redutase , Finasterida/análogos & derivados , Animais , Peso Corporal/efeitos dos fármacos , Di-Hidrotestosterona/farmacologia , Cães , Inibidores Enzimáticos/farmacologia , Finasterida/farmacologia , Humanos , Imageamento por Ressonância Magnética , Masculino , Microssomos/enzimologia , Orquiectomia , Tamanho do Órgão/efeitos dos fármacos , Próstata/enzimologia , Próstata/crescimento & desenvolvimento , RatosRESUMO
Letrozole is a new orally, active, potent, and highly specific non-steroidal aromatase inhibitor. Letrozole is about 200 and 10000 times as potent as aminoglutethimide (AG) in vitro and in vivo, respectively. Letrozole was tested in healthy men and postmenopausal women and in postmenopausal patients with advanced breast cancer (ABC). Levels of circulating estrogens decreased by more than 75 to 95% from pre-treatment levels have been observed in patients treated with daily doses of 0.1 to 5 mg letrozole. No clinically relevant changes in other hormones of the endocrine system were found. In four phase Ib/IIa trials, letrozole has shown anti-tumor activity in postmenopausal patients with ABC previously treated with hormonotherapy and/or chemotherapy. Letrozole was well tolerated. Phase IIb/III studies are on going to compare two doses of letrozole with megestrol acetate or AG in order to confirm the anti-tumor efficacy of letrozole in the treatment of ABC in postmenopausal patients who progressed/relapsed following treatment with anti-estrogens.
Assuntos
Antineoplásicos/uso terapêutico , Inibidores da Aromatase , Neoplasias da Mama/tratamento farmacológico , Inibidores Enzimáticos/uso terapêutico , Nitrilas/uso terapêutico , Triazóis/uso terapêutico , Neoplasias da Mama/metabolismo , Ensaios Clínicos como Assunto , Estrogênios/metabolismo , Estudos de Avaliação como Assunto , Feminino , Humanos , Letrozol , Masculino , Pós-MenopausaRESUMO
The specific role of oestrogen in follicular maturation, ovulation and early embryonic development was investigated using Fadrozole (CGS 16949A), a non-steroidal aromatase inhibitor, to block oestrogen synthesis specifically and effectively in experimental animals. Induced and normal cyclical follicular maturation as well as normal and hCG/LH-induced ovulation were relatively unaffected by significantly depleting oestrogen in all animals (hamsters, rabbits, monkeys) studied other than rats. Fadrozole treatment significantly reduced the number of healthy antral follicles produced and the ovulatory response to exogenous hCG of immature rats primed with pregnant mares' serum gonadotrophin. The effect was specific, in that exogenously administered oestrogen reversed the blockade. Depletion of oestrogen, starting early in pro-oestrus in hamsters, had no effect on ovulation, oocyte maturation and fertilization, as normal implantation sites were seen on day 6 after coitus. In rabbits, oestrogen depletion during the periovulatory phase affected oviductal morphology and function. Although fertilization was not impaired, early embryo development did not appear to be normal. In monkeys, oestrogen depletion during the follicular phase did not lead to a block of follicular maturation or ovulation but resulted in a significant reduction in secretion of cervical mucus. Administration of either Fadrozole or Tamoxifen during the early luteal phase in cyclic monkeys that were allowed to mate prevented implantation and this appears to be due to impaired fertilization or faulty embryo development. These results suggest that, although there is a clear requirement for oestrogen to support the reproductive cycle in the female, the need for oestrogen in regulating specific events is species dependent.
Assuntos
Blastocisto/fisiologia , Desenvolvimento Embrionário e Fetal/fisiologia , Estrogênios/fisiologia , Folículo Ovariano/fisiologia , Ovário/fisiologia , Animais , Gonadotropina Coriônica/farmacologia , Cricetinae , Desenvolvimento Embrionário e Fetal/efeitos dos fármacos , Antagonistas de Estrogênios/farmacologia , Fadrozol/farmacologia , Feminino , Gonadotropinas Equinas/farmacologia , Macaca radiata , Folículo Ovariano/efeitos dos fármacos , Ovário/efeitos dos fármacos , Ovulação/efeitos dos fármacos , Gravidez , Coelhos , Ratos , Ratos Wistar , Especificidade da EspécieRESUMO
The luteotropic action of estrogen (E) was investigated using immature pseudopregnant rat as the model and CGS 16949A (Fadrozole hydrochloride), a potent aromatase inhibitor (AI), to block E synthesis. Aromatase activity could be inhibited by administering CGS 16949A (50 micrograms/day/rat) via a mini osmotic Alzet pump (model 2002) for 3 days during pseudopregnancy. This resulted in significant reduction of serum (40%, P < 0.05) and intraovarian 70.6%, P < 0.001) estradiol-17 beta (E2) levels. The serum and intraovarian progesterone (P4) levels as analyzed on day 4 of pseudopregnancy were also reduced by > or = 50% (for both, P < 0.01). Simultaneous administration of estradiol-3-benzoate (E2B) via an Alzet pump during the AI treatment period at a dose of 1 microgram/day could completely reverse the AI induced reduction in P4 secretion. The luteal cells of experimental rats depleted of E in vivo showed a significantly reduced response upon incubation with hCG or dbcAMP in vitro (P < 0.05 and 0.001, respectively). Addition of E2 (500 pg/tube) at the time of in vitro incubation was able to partially increase the responsiveness to hCG. The luteal cell LH/hCG receptor content and the affinity of hCG binding to the receptor remained unchanged following AI treatment in vivo. Both esterified and total cholesterol content of luteal cells of rats treated with AI in vivo was significantly high (P < 0.05) suggesting that E lack results in an impairment in cholesterol utilization for steroidogenesis. The results clearly show that E regulates luteal function in the pseudopregnant rat by acting at a non-cAMP mediated event and this perhaps involves facilitation of cholesterol utilization at the mitochondrial level for P4 synthesis.
Assuntos
Inibidores da Aromatase , Corpo Lúteo/efeitos dos fármacos , Inibidores Enzimáticos/farmacologia , Antagonistas de Estrogênios/farmacologia , Estrogênios/biossíntese , Fadrozol/farmacologia , Pseudogravidez/metabolismo , Animais , Bucladesina/farmacologia , Células Cultivadas , Colesterol/análise , Gonadotropina Coriônica/farmacologia , Corpo Lúteo/citologia , Corpo Lúteo/metabolismo , Estradiol/biossíntese , Estradiol/sangue , Estradiol/química , Feminino , Ovário/química , Ovário/efeitos dos fármacos , Gravidez , Progesterona/biossíntese , Progesterona/sangue , Progesterona/química , Ratos , Ratos WistarRESUMO
The present study focusses attention on the effects of blocking estrogen synthesis, during follicular phase, on follicular maturation in the adult female bonnet monkey (Macaca radiata). Administration of cycling females (n=4) with an aromatase inhibitor CGS 16949A (Al) by Alzet mini-pump (2,5 mg/day) from day 3 of cycle resulted in significant reduction in basal (by 53%) and surge levels of estrogen (by 70%) but this had no effect on follicular maturation, ovulation and luteal function as assessed by serum hormone profiles as well as laparotomy. This lack of need for estrogen for completion of follicular maturation process was confirmed by administering cycling monkeys hFSH (25 IU/day) from day 3 till day 8 of the cycle along with (5 mg Al/day) or without Al (n=3/group). Administration of AI resulted in suppression of FSH induced increase in serum estrogen (by 100%) and elevation in circulating androstenedione. Aromatase inhibitor treatment had no effect on either the number of follicles developed or their size relative to control. Testing the ability of both granulosa and thecal cells, removed on day 9 of treatment cycle, to respond to gonadotropinsin vitro showed no change indicating that cellular development and maturation of follicular cells had occurred normally. It is concluded that follicular maturation in the primate can occur even when increase in estrogen synthesis is blocked.
RESUMO
While the endocrine role of oestrogen is well established, its function in follicular maturation as an autocrine or paracrine regulator is less well understood. This study was designed to delineate the requirement of oestrogen for follicular development in immature rats. Exogenous gonadotrophin (25 IU pregnant mare serum gonadotrophin (PMSG) per rat) was administered to 21- to 23-day old female rats to induce follicular growth and development. In the experimental animals, synthesis of oestrogen was blocked by implanting an Alzet pump containing the aromatase inhibitor (AI) CGS 16949A (fadrozole hydrochloride; 50 micrograms/rat per day). The treatment resulted in blockade of the PMSG induced increase in both serum and intrafollicular oestrogen (> 95%), thus leading to an inhibition in uterine weight increment. Compared with the controls, ovarian weight increased markedly in both the PMSG (295%)- and PMSG+AI (216%)-primed animals. There was no significant difference in either the proliferative capabilities of the ovarian granulosa cells or their responsiveness to human chorionic gonadotrophin (hCG; 200 pg/ml) and ovine FSH (20 ng/ml) between the PMSG- and PMSG+AI-treated groups. Histological examination of the ovary, however, indicated a decrease in the number of healthy antral follicles in the AI-treated group compared with the PMSG-primed animals but both the groups showed a percentage increase over the controls (PMSG, 225; PMSG+AI, 158). The responsiveness of the animals to an ovulatory dose of hCG was drastically reduced (> 80% inhibition of ovulation) in the oestrogen-deprived animals; this could be overriden by exogenous administration of oestrogen.(ABSTRACT TRUNCATED AT 250 WORDS)
Assuntos
Inibidores da Aromatase , Estrogênios/fisiologia , Fadrozol/farmacologia , Gonadotropinas Equinas/farmacologia , Folículo Ovariano/fisiologia , Animais , Células Cultivadas , Estrogênios/metabolismo , Feminino , Células da Granulosa/efeitos dos fármacos , Tamanho do Órgão/efeitos dos fármacos , Folículo Ovariano/efeitos dos fármacos , Folículo Ovariano/metabolismo , Ovário/anatomia & histologia , Ratos , Ratos WistarRESUMO
The effect of aromatase inhibitors, 4-hydroxyandrostenedione, CGS 16949A and aminoglutethimide on the inhibition of estrogen 2-hydroxylase activity in rat liver microsomes in vitro and on its induction in vivo has been examined. Estrogen 2-hydroxylase was found to have over twice the affinity for estradiol compared to estrone. Using high pressure liquid chromatography and employing estradiol as a substrate, the IC50 values were 2.2, 98, 110 and 908 microM for the reference compound ketoconazole and the aromatase inhibitors, 4-hydroxyandrostenedione, CGS 16949A and aminoglutethimide, respectively. Similar IC50 values were obtained using estrone as a substrate and by a tritiated water method employing estradiol as a substrate. The Km value for estrogen 2-hydroxylase with estradiol as a substrate using a tritiated water method was 4.3 microM with a Vmax of 11.89 nmol/h/mg. Ketoconazole, CGS 16949A and aminoglutethimide exhibited non-competitive inhibition whereas 4-hydroxyandrostenedione appeared to be a competitive inhibitor of estrogen 2-hydroxylase. The Ki values were 2.6, 72, 114 and 958 microM for ketoconazole, 4-hydroxyandrostenedione, CGS 16949A and aminoglutethimide, respectively. All three aromatase inhibitors were weak inhibitors of estrogen 2-hydroxylase as compared to the reference drug, ketoconazole. Following treatment of rats with aminoglutethimide (40 mg/kg/day; i.p.; for 3 days), estrogen 2-hydroxylase activity was increased by 28 and 30% using estradiol and estrone as substrates, respectively. Following treatment of rats with CGS 16949A (2 mg/kg/day; p.o.; for 3 days), the corresponding increase in estrogen 2-hydroxylase activity was 48 and 44%. The results of this study indicate that the aromatase inhibitors, aminoglutethimide and CGS 16949A are only weak inhibitors of estrogen 2-hydroxylase activity in vitro and show no evidence of inhibition in vivo. On the contrary, there was some evidence to suggest that both aminoglutethimide and CGS 16949A induce estrogen metabolism following repeated administration. Therefore, aminoglutethimide and CGS 16949A may lower estrogen levels not only by primarily inhibiting their synthesis but also by inducing the metabolism of estrogens.